BSF Enterprise (LSE:BSFA), the tissue engineering and lab-grown materials biotechnology company, has executed Heads of Terms, with certain provisions legally binding, establishing a strategic partnership with SCHAKAU Managementberatung GmbH.
The deal targets two commercial pillars: bespoke lab-grown leather trim for ultra-luxury vehicle interiors under BSF's T-Rex Leather brand, and bio-engineered human skin equivalents as surface layers for humanoid and industrial robotics.
SCHAKAU will earn a revenue share on programmes it originates, running at the full agreed baseline percentage for the first three years after first commercial production, halving for years four to six, then ceasing.
Capital SCHAKAU introduces attracts a success fee sliding from 5% on the first £10m to 2% above £50m, payable in cash or equity.
BSF retains full ownership of its underlying patents, scaffolds and cell-manufacturing workflows through subsidiaries 3D Bio-Tissues and Lab-Grown Leather.
Any equity or option incentives for SCHAKAU are entirely contingent on hitting defined commercial milestones.
The Heads of Terms target a binding memorandum of understanding for lab-grown leather licensing between September and December, and a binding memorandum with a Tier-1 robotics partner between September and January 2027.
"This strategic partnership represents a significant step in converting our platform science into high-value commercial channels", said BSF chief executive Che Connon, adding the framework "protects our IP while giving our partner every incentive to secure major OEM contracts".
SCHAKAU managing director Nico Schakau said lab-grown leather offers "an extraordinary opportunity to demonstrate what this technology can achieve today", with robotics "a glimpse of what it could become tomorrow".
News Intelligence what this means for the company
BSF Enterprise has signed Heads of Terms with SCHAKAU Managementberatung to commercialise lab-grown leather in ultra-luxury automotive interiors and bio-engineered skin for robotics, under a six-year revenue-share model where SCHAKAU originates deals and earns a sliding success fee (5% on the first £10m, declining to 2% above £50m). BSF retains full IP ownership and patent control through subsidiaries 3D Bio-Tissues and Lab-Grown Leather, with SCHAKAU's equity incentives contingent on hitting commercial milestones—a structure that mirrors the company's earlier ETSYL cosmetics licensing deal with SCHAKAU in August 2026, where the licensing structure produces supply revenue without requiring fresh development capital from BSF.
The deal extends BSF's commercialisation reach into two new verticals (automotive luxury trim and robotics) without diluting equity or requiring fresh capital, following the proven SCHAKAU partnership model. The binding timelines—lab-grown leather licensing by December 2026 and a Tier-1 robotics partner MOU by January 2027—will test whether the company can convert platform science into OEM contracts at scale.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
